Multidrug resistance in yeast Candida.

Area of Science:

• Medical Mycology
• Antimicrobial Resistance
• Molecular Biology

Background:

• Opportunistic fungal pathogens like Candida albicans pose increasing threats to immunocompromised individuals.
• Candida species infections are severe and complicated by the development of antifungal resistance.
• The widespread use of azole antifungals has accelerated the emergence of multidrug resistance (MDR).

Purpose of the Study:

• To investigate the mechanisms underlying azole resistance in Candida species.
• To identify key molecular players contributing to multidrug resistance in clinical isolates.

Main Methods:

• Analysis of target enzyme (lanosterol 14 alpha-demethylase) mutations and overexpression.
• Investigating the transcriptional activation of drug efflux pump genes.
• Studying ATP-binding cassette (ABC) and major facilitator superfamily (MFS) transporters.

Main Results:

• Overexpression of or mutations in lanosterol 14 alpha-demethylase contribute to azole resistance.
• Transcriptional activation of drug efflux pump genes, including ABC transporters (CDR1, CDR2) and MFS transporters (CaMDR1), is implicated in MDR.
• High expression levels of CDR1, CDR2, and CaMDR1 were observed in azole-resistant clinical isolates.

Conclusions:

• Mechanisms of MDR in Candida involve alterations in azole targets and increased activity of drug efflux pumps.
• ABC and MFS transporters, particularly CDR1, CDR2, and CaMDR1, are crucial for azole resistance in Candida.
• Understanding these resistance mechanisms is vital for developing effective antifungal therapies against Candida infections.